Francis McCormick

Francis Patrick McCormick is the founder of BridgeBio Pharma LLC, founded in 2015.
Dr. McCormick was the founder of Onyx Pharmaceuticals, Inc., founded in 1992, and served as Chief Scientific Officer from 1992 to 1996.
Dr. McCormick was the founder of Avidity Biosciences, Inc., founded in 2012, and served as Director.
Dr. McCormick is the founder of BridgeBio Pharma, Inc., founded in 2015, and holds the title Director & Chairman-Oncology since 2023.
Dr. McCormick is also the founder of DNAtrix, Inc...
Dr. McCormick is currently Director at PellePharm, Inc., Arresto BioSciences, Inc., Melanoma Therapeutics Foundation, Navire Pharma, Inc., and holds the position of Independent Director at Bridgebio Oncology Therapeutics, Inc. Dr. McCormick is Director at UCSF Helen Diller Family Comprehensive Cancer Center since 1997.
Dr. McCormick is a Member of the National Academy of Sciences since 2014.
Former positions include Independent Director at Exelixis, Inc. from 2011 to 2014, Independent Director at Aduro BioTech, Inc. from 2010 to 2019, Director at Peloton Therapeutics, Inc., Independent Director at Olema Pharmaceuticals, Inc. from 2014 to 2021, Vice President-Research at Chiron Corp.
from 1991 to 1992, Vice President-Discovery Research at Cetus Corp.
from 1991 to 1992, President of the American Association for Cancer Research in 2013, and Associate Dean at UCSF School of Medicine from 1997 to 2014.
Education includes a doctorate from the University of Cambridge conferred in 1975 and an undergraduate degree from the University of Birmingham conferred in 1972.